MACROGENICS INC
MGNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MGNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGNX
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer, with three FDA-approved products out-licensed to partners and a pipeline of proprietary and collaborative programs in clinical and preclinical development.
Key risk: Clinical development risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 19 clinical trials · 1 FDA decision for MACROGENICS INC.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer, with three FDA-approved products out-licensed to partners and a pipeline of proprietary and collaborative programs in clinical and preclinical development.
- MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer [sec_mda · as of 2026-05-13].
- The company has three FDA-approved products out-licensed to partners: ZYNYZ (retifanlimab-dlwr), MARGENZA (margetuximab-cmkb), and TZIELD (teplizumab-mzwv) [sec_mda · as of 2026-08-14].
- MacroGenics is advancing three proprietary clinical-stage candidates: lorigerlimab (bispecific targeting PD-1 and CTLA-4), MGC026 (ADC targeting B7-H3), and MGD024 (bispecific targeting CD123 and CD3, in collaboration with Gilead) [sec_mda · as of 2026-05-13].
- As of June 30, 2026, the company reported cash and equivalents of $113.9M, total revenue of $32.8M, net income of $19.5M, and shareholders' equity of $55.6M [sec].
- The company operates a commercial-scale cGMP antibody manufacturing facility in Maryland and provides contract development and manufacturing services to collaborators and third parties [sec_mda · as of 2026-05-13].
What works
- MacroGenics has generated over $1.6 billion in non-dilutive funding from strategic collaborations since its inception in 2000, supporting its pipeline and operations [sec_mda · as of 2026-03-09].
- The company has three FDA-approved products (ZYNYZ, MARGENZA, TZIELD) that have been out-licensed or sold to partners, providing potential royalty and milestone revenue streams [sec_mda · as of 2026-08-14].
- MacroGenics' proprietary DART and TRIDENT platforms have enabled multiple product candidates and collaborations, including a partnership with Gilead on MGD024 [sec_mda · as of 2026-05-13].
What to weigh
- MacroGenics is a clinical-stage company that only began generating product sales revenue in 2021, and its ability to fund operations depends on future financing and collaboration payments [sec_mda · as of 2026-05-13].
- The company's manufacturing operations (CDMO) have been sold, as noted in subsequent events, which may reduce its ability to offset facility operating costs [sec_mda · as of 2026-05-13].
- MacroGenics' pipeline is heavily reliant on the success of clinical-stage candidates (lorigerlimab, MGC026, MGD024), which face inherent development and regulatory risks [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
MacroGenics has three FDA-approved products out-licensed to partners.
“These include three products approved by the FDA: ZYNYZ ® (retifanlimab-dlwr), an anti-PD-1 monoclonal antibody (mAb) that the Company out-licensed; MARGENZA ® (margetuximab-cmkb), an anti-HER2 mAb that the Company sold to a partner; and TZIELD ® (teplizumab-mzwv), an anti-CD3 mAb that the Company sold to a partner.”
SEC MD&A · August 14, 2026
MacroGenics has generated over $1.6 billion in non-dilutive funding from collaborations.
“These collaborations have provided us with over $1.6 billion of non-dilutive funding since our inception in 2000”
SEC MD&A · March 9, 2026
MacroGenics is advancing three proprietary clinical-stage candidates.
“The Company is currently advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based lin”
SEC MD&A · May 13, 2026
Risks & what to watch (4)›
Key risks
- Clinical development risk — Pipeline candidates (lorigerlimab, MGC026, MGD024) are in clinical stages and may fail to demonstrate safety or efficacy [sec_mda · as of 2026-05-13].
- Dependence on partnerships — Revenue and funding rely heavily on collaborations (e.g., Gilead) and out-licensed products, which may not generate expected returns [sec_mda · as of 2026-05-13].
- Manufacturing operations sale — Sale of CDMO operations may reduce revenue from contract manufacturing and increase facility costs [sec_mda · as of 2026-05-13].
- Financing uncertainty — As a clinical-stage company, MacroGenics may need additional capital to fund operations, with no guarantee of availability [sec_mda · as of 2026-05-13].
What to watch
- Clinical trial data readouts for lorigerlimab, MGC026, and MGD024 [sec_mda · as of 2026-05-13].
- Updates on the Gilead collaboration for MGD024 and any new partnership announcements [sec_mda · as of 2026-05-13].
- Financial performance, particularly revenue from out-licensed products and collaboration milestones [sec_mda · as of 2026-08-14].
- Progress of preclinical ADC and T-cell engager programs [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run MACROGENICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MACROGENICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
13.0 months
D/E 7.06 · 0% dilution
Lead: Approved
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
109
Total value held
$125.6M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 6,012,000 | $17.4M |
| vanguard capital management llc | 5,307,706 | $15.3M |
| renaissance technologies llc | 2,963,559 | $8.6M |
| millennium management llc | 2,794,357 | $8.1M |
| two sigma investments, lp | 2,527,829 | $7.3M |
| bank of america corp /de/ | 2,401,814 | $6.9M |
| marshall wace, llp | 2,025,526 | $5.9M |
| ra capital management, l.p. | 1,864,176 | $5.4M |
| wasatch advisors lp | 1,559,701 | $4.5M |
| vanguard portfolio management llc | 1,208,775 | $3.5M |
Showing top 10 of 109 institutional holders of MACROGENICS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 6.2%
- Days to cover
- 2.4
- Shares short
- 3,778,755
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MACROGENICS INC?
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer, with three FDA-approved products out-licensed to partners and a pipeline of proprietary and collaborative programs in clinical and preclinical development.
What is MACROGENICS INC's lead drug candidate?
MACROGENICS INC's most advanced tracked candidate is IMGC936 (Phase 1) for ADAM9-expressing tumors (solid tumors).
Who is the CEO of MACROGENICS INC?
Mr. Eric Blasius Risser is the chief executive officer of MACROGENICS INC (MGNX).
Where is MACROGENICS INC headquartered?
MACROGENICS INC (MGNX) is headquartered in Rockville, MD, United States.
What therapeutic areas does MACROGENICS INC focus on?
MACROGENICS INC develops therapies across Oncology, Immunology, Infectious Disease, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.